Synthesis and Evaluation of a Novel Small-molecule Compound as an Anticancer Inhibitor of CD147

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
• Cluster of Differentiation 147 (CD147) is implicated in tumor progression, but its precise role in cancer cell malignancy requires further elucidation.
• Existing CD147-targeting agents like AC-73 have limitations, highlighting the need for more potent compounds.

Purpose of the Study:

• To investigate the correlation between CD147 expression levels and cancer cell malignancy.
• To synthesize and evaluate novel compounds targeting CD147 for enhanced anticancer efficacy.
• To elucidate the molecular mechanisms underlying the action of promising new anticancer agents.

Main Methods:

• In vitro proliferation assays (Wst-1) and apoptosis assessments.
• In vivo efficacy and safety studies using a nude mouse model.
• Western blot analysis to determine the molecular mechanism of action.

Main Results:

• A positive correlation was observed between CD147 expression and tumor cell proliferation.
• The novel compound HA-08 demonstrated superior anticancer activity compared to AC-73, inhibiting cancer cell viability and promoting apoptosis both in vitro and in vivo.
• HA-08 functions by disrupting the CD147-CD44 interaction, leading to the downregulation of the JAK/STAT3/Bcl-2 signaling pathway and subsequent cancer cell apoptosis.

Conclusions:

• CD147 exhibits tumor-specific characteristics and serves as a viable drug target.
• The synthesized compound HA-08 possesses a favorable biological profile and demonstrates significant potential for development as a novel anticancer therapeutic agent.